biomarker severity from CON to AD, with SCD showing a small, but significant difference from CON in the EC and HPC. Results: Qualitatively, morphometry results showed a gradient of changes from CON to AD in the EC and HPC (Figure 1 ), especially for the left EC and right HPC, but with SCD not significantly different from CON. Furthermore, compared to CON, SCD had significant lower right lingual surface (p¼.021), left posterior cingulate thickness (p¼.026), right rostral anterior cingulate thickness (p¼.012), left supramarginal surface (p¼.019) and volume (p¼.039), however none of those differences resisted FDR correction. Grading results ( Figure 2 ) were similar to morphometry, with a gradient of changes from CON to AD, especially for the left EC and right HPC, but no significant difference between SCD and CON. Conclusions: Based on these results, baseline morphometric measures and TPMD grading scores for EC and HPC do not capture the difference related to the cognitive complaint between SCD and CON. Longitudinal follow-up is required to determine their positive predictive values for AD pathology. Longitudinal Magnetic Resonance Imaging (MRI-T13D) data was acquired from a subset of the ADNI cohort comprising 817 subjects (174 controls, 125 preclinical, 518 MCI/Dementia due to AD, at baseline) for which cerebrospinal fluid (CSF) biomarker data is publicly available. For each subject, volumetric changes in brain structure between two consecutive acquisition timepoints (average time interval of 2 years) were defined by calculating jacobian determinants using the SPM longitudinal Voxel-Based Morphometry pipeline. Statistical analysis was performed to identify brain regions with significantly different changes between five progressive groups: (1) Normal controls, (2) Normal control subjects that convert to amyloid positive, (3) Preclinical subjects, (4) Preclinical subjects that become symptomatic, (5) Symptomatic (MCI and AD) subjects. Results: We define the preclinical AD signature as statistically significant structural brain changes between normal controls vs. preclinical subjects (group 1 vs 3). We found certain brain regions that show early subtle atrophy (e.g. Middle Temporal). Other regions show volume increments (e.g. Hippocampus) whereas they display longitudinal atrophy in symptomatic stages (Figure 1 ), probably resulting in expansion of CSF. Thus, the characterized preclinical AD signature presents regions that overlap with the well-established AD signature (e.g. Precuneus), and others that do not (e.g. Caudate). We will also describe changes that are specific for groups (2) and (4). Conclusions: Our work supports the idea that there are brain volumetric changes specific to preclinical AD subjects and defines the preclinical AD
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